Targeted therapies might also enhance the presentation of tumor antigens to immune cells, improving the priming of tumor-specific T cells as well as targeting EGFR, VEGFR, or BRAF, which are frequently mutated or dysregulated in GI cancers [165]. This evidence concerns the gene BRAF and neoplasm.